^
No biomarker
|
Urothelial Cancer
|
enfortumab vedotin Sensitive: A1 - Approval
Seagen Press Release - 1 day
|
enfortumab vedotin Sensitive: A1 - Approval
Seagen Press Release - 1 day
|
No biomarker
|
Prostate Cancer
|
olaparib Sensitive: B - Late Trials
Merck (MSD) Press Release - 4 days
|
olaparib Sensitive: B - Late Trials
Merck (MSD) Press Release - 4 days
|
FGFR3 mutation
|
Urothelial Cancer
|
TAS 120 Sensitive: C2 – Inclusion Criteria
Cancer Discov - 6 days
|
TAS 120 Sensitive: C2 – Inclusion Criteria
Cancer Discov - 6 days
|
FGFR1 mutation
|
Urothelial Cancer
|
TAS 120 Sensitive: C3 – Early Trials
Cancer Discov - 6 days
|
TAS 120 Sensitive: C3 – Early Trials
Cancer Discov - 6 days
|
BRCA2 mutation
|
Prostate Cancer
|
olaparib Sensitive: A1 - Approval
CAP 2021 - 1 week
|
olaparib Sensitive: A1 - Approval
CAP 2021 - 1 week
|
PD-L1 expression
|
Urothelial Cancer
|
atezolizumab Sensitive: A1 - Approval
ESMO 2021 - 2 weeks
|
atezolizumab Sensitive: A1 - Approval
ESMO 2021 - 2 weeks
|
VHL mutation
|
RCC
|
belzutifan Sensitive: A1 - Approval
NCCN - 2 weeks
|
belzutifan Sensitive: A1 - Approval
NCCN - 2 weeks
|
FGFR mutation
|
Urothelial Cancer
|
erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
AR-V7 positive
|
Prostate Cancer
|
cabazitaxel Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
cabazitaxel Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
NANOGNB mutation
|
Clear Cell Renal Cell Carcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
Immunotherapy Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
BRCA2 mutation
|
Prostate Cancer
|
avelumab Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
avelumab Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
ATM mutation
|
Prostate Cancer
|
avelumab Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
avelumab Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
CXCL13 elevation
|
Clear Cell Renal Cell Carcinoma
|
nivolumab Resistant: C3 – Early Trials
ESMO 2021 - 2 weeks
|
nivolumab Resistant: C3 – Early Trials
ESMO 2021 - 2 weeks
|
TNFSF13B elevation
|
Clear Cell Renal Cell Carcinoma
|
nivolumab Resistant: C3 – Early Trials
ESMO 2021 - 2 weeks
|
nivolumab Resistant: C3 – Early Trials
ESMO 2021 - 2 weeks
|
IL6 elevation
|
Clear Cell Renal Cell Carcinoma
|
nivolumab Resistant: C3 – Early Trials
ESMO 2021 - 2 weeks
|
nivolumab Resistant: C3 – Early Trials
ESMO 2021 - 2 weeks
|
PTEN mutation
|
Prostate Cancer
|
enzalutamide + CC-115 Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
enzalutamide + CC-115 Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
PTEN deletion
|
Prostate Cancer
|
enzalutamide + CC-115 Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
enzalutamide + CC-115 Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
FGFR fusion
|
Urothelial Cancer
|
erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
FOLH1 expression
|
Prostate Cancer
|
pembrolizumab + 177 Lu PSMA-617 Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
pembrolizumab + 177 Lu PSMA-617 Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
CD276 overexpression
|
Prostate Cancer
|
DS-7300 Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
DS-7300 Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
TMB-H
|
Prostate Cancer
|
pembrolizumab + enzalutamide Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
pembrolizumab + enzalutamide Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
EPHB2 expression
|
Urothelial Cancer
|
pembrolizumab + sEphB4-HSA Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
pembrolizumab + sEphB4-HSA Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
|
No biomarker
|
RCC
|
nivolumab + cabozantinib tablet Sensitive: A1 - Approval
|
nivolumab + cabozantinib tablet Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
apalutamide Sensitive: A1 - Approval
|
apalutamide Sensitive: A1 - Approval
|
No biomarker
|
Urothelial Cancer
|
avelumab Sensitive: A1 - Approval
|
avelumab Sensitive: A1 - Approval
|
No biomarker
|
Urothelial Cancer
|
sacituzumab govitecan-hziy Sensitive: A1 - Approval
|
sacituzumab govitecan-hziy Sensitive: A1 - Approval
|
PD-L1 expression
|
RCC
|
avelumab + axitinib Sensitive: A1 - Approval
|
avelumab + axitinib Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
histrelin acetate Sensitive: A1 - Approval
|
histrelin acetate Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
cabazitaxel Sensitive: A1 - Approval
|
cabazitaxel Sensitive: A1 - Approval
|
BRCA1 mutation
|
Prostate Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
avelumab + axitinib Sensitive: A1 - Approval
|
avelumab + axitinib Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
enzalutamide Sensitive: A1 - Approval
|
enzalutamide Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
relugolix Sensitive: A1 - Approval
|
relugolix Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
sorafenib Sensitive: A1 - Approval
|
sorafenib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
tivozanib Sensitive: A1 - Approval
|
tivozanib Sensitive: A1 - Approval
|
No biomarker
|
Urothelial Cancer
|
mitomycin urothelial gel Sensitive: A1 - Approval
|
mitomycin urothelial gel Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
temsirolimus Sensitive: A1 - Approval
|
temsirolimus Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
sunitinib Sensitive: A1 - Approval
|
sunitinib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
everolimus + lenvatinib Sensitive: A1 - Approval
|
everolimus + lenvatinib Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
docetaxel + prednisone Sensitive: A1 - Approval
|
docetaxel + prednisone Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
abiraterone acetate Sensitive: A1 - Approval
|
abiraterone acetate Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
everolimus Sensitive: A1 - Approval
|
everolimus Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
degarelix Sensitive: A1 - Approval
|
degarelix Sensitive: A1 - Approval
|
PD-L1 expression
|
Urothelial Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval
|
bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval
|
ATM mutation
|
Prostate Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
darolutamide Sensitive: A1 - Approval
|
darolutamide Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
cabozantinib tablet Sensitive: A1 - Approval
|
cabozantinib tablet Sensitive: A1 - Approval
|
No biomarker
|
Bladder Cancer
|
cisplatin Sensitive: A1 - Approval
|
cisplatin Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
pembrolizumab + lenvatinib Sensitive: A1 - Approval
|
pembrolizumab + lenvatinib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
pembrolizumab + axitinib Sensitive: A1 - Approval
|
pembrolizumab + axitinib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
FGFR2 mutation
|
Urothelial Cancer
|
erdafitinib Sensitive: A1 - Approval
|
erdafitinib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Urothelial Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
No biomarker
|
Urothelial Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
FGFR3 mutation
|
Urothelial Cancer
|
erdafitinib Sensitive: A1 - Approval
|
erdafitinib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
axitinib Sensitive: A1 - Approval
|
axitinib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
pazopanib Sensitive: A1 - Approval
|
pazopanib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Prostate Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
BRCA2 mutation
|
Prostate Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
aldesleukin Sensitive: A1 - Approval
|
aldesleukin Sensitive: A1 - Approval
|
No biomarker
|
Urothelial Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
HRD
|
Prostate Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
zoledronic acid Sensitive: A1 - Approval
|
zoledronic acid Sensitive: A1 - Approval
|
PD-L1 overexpression
|
Urothelial Cancer
|
tislelizumab Sensitive: A1 - Approval
|
tislelizumab Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Urothelial Cancer
|
toripalimab Sensitive: A1 - Approval
|
toripalimab Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
leuprolide mesylate injectable suspension Sensitive: A1 - Approval
|
leuprolide mesylate injectable suspension Sensitive: A1 - Approval
|
No biomarker
|
Bladder Cancer
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Prostate Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
mitoxantrone Sensitive: A2 - Guideline
|
mitoxantrone Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
etoposide IV Sensitive: A2 - Guideline
|
etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
atezolizumab Sensitive: A2 - Guideline
|
atezolizumab Sensitive: A2 - Guideline
|
No biomarker
|
RCC
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline
|
bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline
|
PD-L1 expression
|
Bladder Cancer
|
atezolizumab Sensitive: A2 - Guideline
|
atezolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Bladder Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
avelumab + axitinib Sensitive: A2 - Guideline
|
avelumab + axitinib Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
pembrolizumab + axitinib Sensitive: A2 - Guideline
|
pembrolizumab + axitinib Sensitive: A2 - Guideline
|
No biomarker
|
RCC
|
bevacizumab + erlotinib Sensitive: A2 - Guideline
|
bevacizumab + erlotinib Sensitive: A2 - Guideline
|
No biomarker
|
RCC
|
erlotinib Sensitive: A2 - Guideline
|
erlotinib Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
carboplatin + etoposide IV Sensitive: A2 - Guideline
|
carboplatin + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive: A2 - Guideline
|
cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
enfortumab vedotin Sensitive: A2 - Guideline
|
enfortumab vedotin Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
paclitaxel + gemcitabine Sensitive: A2 - Guideline
|
paclitaxel + gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
carboplatin + gemcitabine Sensitive: A2 - Guideline
|
carboplatin + gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Bladder Cancer
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
CDK12 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
PALB2 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
No biomarker
|
Urothelial Cancer
|
durvalumab Sensitive: A2 - Guideline
|
durvalumab Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
sunitinib Sensitive: A2 - Guideline
|
sunitinib Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
pazopanib Sensitive: A2 - Guideline
|
pazopanib Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
temsirolimus Sensitive: A2 - Guideline
|
temsirolimus Sensitive: A2 - Guideline
|
CHEK2 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
CHEK1 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
AR splice variant 7
|
Prostate Cancer
|
abiraterone acetate Resistant: A2 - Guideline
|
abiraterone acetate Resistant: A2 - Guideline
|
AR splice variant 7
|
Prostate Cancer
|
enzalutamide Resistant: A2 - Guideline
|
enzalutamide Resistant: A2 - Guideline
|
RAD51B mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
